GE Diamond DNP Polarizer

GE钻石DNP偏光镜

• 批准号: 8640664
• 负责人: Hedvig Hricak
• 金额: $ 60万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-06-01 至 2015-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8640664
• 关键词: 2,4-Dinitrophenol; Basic Science; Biological Markers; Clinical; Clinical Sciences; Clinical Trials; Complement; Data; Databases; Diamond; Disease; Emerging Technologies; Faculty; Funding; Genomics; Goals; Housing; Human; Image; Imaging technology; Magnetic Resonance Imaging; Malignant Neoplasms; Memorial Sloan-Kettering Cancer Center; Metabolic; Metabolism; Methods; Molecular; Patients; Performance; Positron-Emission Tomography; Public Health; Recurrence; Time; Tissues; Treatment Protocols; base; disease diagnosis; in vivo; innovation; magnetic resonance spectroscopic imaging; molecular imaging; multidisciplinary; novel; oncology; patient population; preclinical study; response; technology development; tumor

DESCRIPTION (provided by applicant): This S10 proposal aims at funding the purchase of a GE Diamond DNP Polarizer for clinical magnetic resonance spectroscopic imaging (MRSI) of hyperpolarized 13C agents, to be housed in the new Center for Integrated Metabolic Imaging (CIMI) at Memorial Sloan-Kettering Cancer Center. There is a great unmet need for more precise and versatile whole-body molecular imaging technologies, and the development of such means would have an enormous public-health impact. Hyperpolarized MRSI (HP- MRSI) is an emerging technology with the unique capacity to image a large variety of metabolic processes in near real-time in vivo and three-dimensionally. Based on the promising data from preclinical studies and the first clinical trial using hyperpolarized MRSI, it is expected that its clinical implementation will have a significant impact on many aspects of oncology, including the ability to elucidate disease mechanisms noninvasively, diagnose disease and its recurrence earlier, and stratify patients for appropriate treatment regimens more rapidly. The GE Diamond DNP Polarizer is the first and currently only commercially available polarizer for use in humans. Via its central installation in CIMI, we propose to make the Diamond Polarizer the nidus of innovation in a unique new facility equipped with the most cutting-edge clinical molecular imaging capabilities, including integrated whole-body MR-PET and multinuclear-capable MR scanners. This will, for the first time, allow the performance of combined HP-MRSI/MRI/PET imaging in human patients, enabling these methods to complement and cross-validate each other synergistically. We have assembled a multidisciplinary team of experts from basic science and clinical departments to successfully implement HP-MRSI and to target specific clinical questions using HP-MRSI and the unique combination of HP-MRSI/MRI/PET. Large patient populations, extensive patient databases, tissue databanks, routine molecular and genomic profiling of tumors, and the diversity and expertise of our clinical and basic science faculty will allow us to correlate the metabolic signatures identified with HP-MRSI with the molecular composition of tumors. This, in turn, will increase the chances of achieving the central goal of this application, which is to establish novel HP-MRSI biomarkers of cancer and its response to treatment.

描述（由申请人提供）：该S10提案旨在资助购买超极化13C代理的GE Diamond DNP偏光剂用于临床磁共振光谱成像（MRSI），该成像（MRSI）将安置在纪念Sloore Sloan-Sloan-kettering cantering Cancer Center的新型综合代谢成像中心（CIMI）。对更精确和多才多艺的全身分子成像技术的需求很大，这种手段的发展将产生巨大的公共卫生影响。超极化MRSI（HP-MRSI）是一项新兴技术，具有独特的能力，可以在体内和三维的实时实时成像各种代谢过程。基于临床前研究的有希望的数据和使用超极化MRSI的首次临床试验，预计其临床实施将对肿瘤学的许多方面产生重大影响，包括毫无创新的疾病机制，较早地诊断疾病及其再生，并为适当的治疗方案分层以更快地诊断疾病。 GE Diamond DNP偏振器是第一个，目前仅用于人类使用的市售偏振器。通过其在CIMI的中央装置，我们建议将钻石偏光层成为一家独特的新设施中的创新，配备了最尖端的临床分子成像能力，包括整体化的MR MR-PET和综合竞争性竞争性MR MR扫描仪。这将首次允许在人类患者中进行HP-MRSI/MRI/PET成像组合的性能，从而使这些方法能够协同补充和交叉验证。我们已经组建了一个来自基础科学和临床部门的专家组成的多学科团队，以成功实施HP-MRSI，并使用HP-MRSI和HP-MRSI/MRI/PET的独特组合来针对特定的临床问题。大量的患者人群，广泛的患者数据库，组织数据库，常规的分子和基因组分析以及我们的临床和基础科学教师的多样性和专业知识 允许我们将与HP-MRSI鉴定的代谢特征与肿瘤的分子组成相关联。反过来，这将增加实现该应用的核心目标的机会，即建立新型的HP-MRSI癌症及其对治疗的反应。